Clarity Pharmaceuticals Stock Performance
| CLRPF Stock | 2.55 0.17 6.25% |
The firm shows a Beta (market volatility) of 0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Clarity Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Clarity Pharmaceuticals is expected to be smaller as well. At this point, Clarity Pharmaceuticals has a negative expected return of -0.89%. Please make sure to confirm Clarity Pharmaceuticals' treynor ratio, and the relationship between the standard deviation and kurtosis , to decide if Clarity Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Clarity Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Clarity |
Clarity Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 500.00 in Clarity Pharmaceuticals on October 9, 2024 and sell it today you would lose (245.00) from holding Clarity Pharmaceuticals or give up 49.0% of portfolio value over 90 days. Clarity Pharmaceuticals is currently producing negative expected returns and takes up 6.4396% volatility of returns over 90 trading days. Put another way, 57% of traded pink sheets are less volatile than Clarity, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Clarity Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clarity Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Clarity Pharmaceuticals, and traders can use it to determine the average amount a Clarity Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1382
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLRPF |
Estimated Market Risk
| 6.44 actual daily | 57 57% of assets are less volatile |
Expected Return
| -0.89 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clarity Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clarity Pharmaceuticals by adding Clarity Pharmaceuticals to a well-diversified portfolio.
Things to note about Clarity Pharmaceuticals performance evaluation
Checking the ongoing alerts about Clarity Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Clarity Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clarity Pharmaceuticals generated a negative expected return over the last 90 days | |
| Clarity Pharmaceuticals has high historical volatility and very poor performance |
- Analyzing Clarity Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clarity Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Clarity Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clarity Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clarity Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clarity Pharmaceuticals' pink sheet. These opinions can provide insight into Clarity Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Clarity Pink Sheet analysis
When running Clarity Pharmaceuticals' price analysis, check to measure Clarity Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clarity Pharmaceuticals is operating at the current time. Most of Clarity Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Clarity Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clarity Pharmaceuticals' price. Additionally, you may evaluate how the addition of Clarity Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |